Mutation status in yes-associated protein 1 (YAP1) in an insulinoma cell line Rin-5F

Previous research indicates that YAP1 mutations may enhance responses to immune checkpoint inhibitors, and this mutation could serve as a novel predictor of response to immunotherapy across various cancers by increasing mutation counts. The insulin-secreting pancreatic cell line Rin-5F is commonly used in pharmacological and toxicological studies. In the present study, the author has examined mutations in the YAP1 gene using genomic DNA and complementary DNA from Rin-5F cells. No mutations in the YAP1 gene were identified in the current investigation. The status of the YAP1 gene in an insulinoma cell line has not been previously documented. According to previous research, YAP1 mutations may be associated with enhanced responses to immune checkpoint inhibitors. Given that there is no mutation of the YAP1 gene in this insulinoma cell line, it is possible that immune checkpoint inhibitors may have a reduced impact on insulinoma. To address this question, further clinical trials of immune checkpoint inhibitors are needed for neuroendocrine tumors, such as insulinomas.